Clinical Trial Update: A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older [Phase 3]

View source ↗

Summary

Phase 3 study evaluating safety and efficacy of once-daily ciclesonide HFA for perennial allergic rhinitis in individuals 12 years and older; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Perennial Allergic Rhinitis

Drugs mentioned

• Ciclesonide HFA (ciclesonide)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Allergic Rhinitis, Perennial Allergic Rhinitis | Phase 3 | Status: COMPLETED | Results posted: 2012-06-07